Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Lancet Respir Med. 2014 May 15;2(7):539–547. doi: 10.1016/S2213-2600(14)70100-6

Figure 3.

Figure 3

Mean relative change in percent-predicted FEV1 from baseline to week 48, by chronic inhaled antibiotic use in the intention-to-treat population (A) Patients who were not taking tobramycin (either no antibiotics or antibiotics other than tobramycin) chronically at baseline. (B) Patients who were taking tobramycin (either alone or in combination with other antibiotics) chronically. Datapoints show the mean change in FEV1 since baseline at each timepoint; error bars show SE. FEV1=forced expiratory volume in 1 s